PW01-025 – Definition of colchicine resistance in FMF
نویسندگان
چکیده
E Demirkaya, C Acikel, A Tufan, A Kucuk, A Berdeli, A Gul, AM Onat, A Delibas, A Duzova, A Dinc, O Yavascan, O Kasapcopur, B Makay, B Goker, B Sozeri, B Kisacik, E Comak, E Unsal, E Erken, E Gunal, E Baskin, F Yalcinkaya, F Yildiz, F Gok, G Basbozkurt, G Ozcelik, G Demircin, H Poyrazoglu, H Erdem, H Direskeneli, H Ozer, H Ozdogan, I Simsek, I Dursun, I Gokce, M Tunca, M Gurgoze, N Cakar, N Akinci, N Ayaz, O Donmez, O Ozkaya, R Topaloglu, S Kavukcu, S Yuksel, S Akar, S Bakkaloglu, S Emre, S Senel, S Erten, S Yavuz, S Kalman, T Kasifoglu, U Kalyoncu, Y Tabel, Z Ekinci, S Ozen, Turkish FMF Study Group, FMF Arthritis Vasculitis and Orphan disease Research in Pediatric Rheumatology (FAVOR)
منابع مشابه
PW01-031 – Treatment of FMF in middle and old age
Introduction Current recommendations for the treatment of familial Mediterranean fever (FMF) are based largely on the observation of FMF patients receiving colchicine therapy in childhood and young age. The adequate colchicine therapy led to more and more patients survive to that age. In addition, there are national peculiarities of FMF. For example, in Armenia, even before the massive use of c...
متن کاملPW01-007 – Colchicine brand switching in FMF patients
Introduction In July of 2009 the U.S. Food and Drug Administration enacted new regulation of colchicine under the “Unapproved Drugs Program.” Like other old drugs that were on the market before the existence of the FDA, colchicine had never been subjected to FDA-required safety and efficacy trials. One company elected to put colchicine through the FDA’s approval protocol and when approval was g...
متن کاملPW01-015 – Canakinumab in adults with colchicin resistant FMF
Introduction Familial Mediterranean fever (FMF) is associated with variations in the MEFV gene resulting in proteolytic activation of IL-1b through the inflammasome complex. There is no established treatment available for those resistant or intolerant to standard of care colchicine treatment. Canakinumab, a fully human selective anti-IL-1b monoclonal antibody with a half-life of ~4-weeks binds ...
متن کاملPW01-010 – The effect of pregnancy on disease course in FMF
Methods All pregnant FMF patients treated at the FMF clinic of the Sheba Medical Center from May 2010 onwards, consenting to participate in this observational study, were studied prospectively for the occurrence of attacks. Attacks were recorded by patients in diaries provided on enrollment and relied by phone to a study coordinator on a monthly telephone call or on a pre-specified physician vi...
متن کاملPW01-018 – Circulating endothelial biomarkers in FMF
Methods Forty FMF patients and eighteen healthy controls with no known cardiovascular risk factors were included. All patients were receiving regular colchicine treatment and examinations were performed during attack-free periods. Serum samples were used for the determination of high sensitive C-reactive protein (hs-CRP), tissue factor (TF), tissue plasminogen activator (t-PA) and osteoproteger...
متن کامل